Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Neurizon Therapeutics.
RELATED STOCKHEAD STORIES
Health & Biotech
PharmAust partners with US-based Berry Consultants for Phase 2/3 study
News
In Case You Missed It: Gold, uranium and a sudden leadership spill are driving the news today
Health & Biotech
ASX Health Stocks: Immuron chalks up record half for travelers’ diarrhoea medicine, Travelan
News
In Case You Missed It: Lithium, chocolate and an IVF tech distribution deal
Health & Biotech
PharmAust just got a pre-IND meeting with the US FDA to kick off ‘24
News
In Case You Missed It: A plethora of acquisitions in the works and some tungsten
Health & Biotech
Up to $1.8m funding from motor neurone disease foundation could be on the table for PharmAust
News
In Case You Missed It: Lithium, tyre recycling and copper-gold drilling
Health & Biotech
Santa (and ATO) delivers PharmAust $550k cash boost for Christmas
News
In Case You Missed It: A new iron ore MD and an $8.8bn pharmacy merger
Health & Biotech
Prominent Perth fundie the main backer in PharmAust’s $3.5m cap raise
News
Rise and Shine: Everything you need to know before the ASX opens
News
Closing Bell: The ASX is spectacularly flat on Monday
News
In Case You Missed It: A lithium project acquisition and a West African gold and lithium hunt
Health & Biotech
PharmAust bolsters leadership as CEO attends global ALS/MND Symposium
News
In Case You Missed It: A Chilean silver mine and $1m worth of lithium rights
Health & Biotech
